Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.57 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298592 | 0.93 | CAMKK2 (0.52) | PIK3CATNIKBRD4NEK1NTRK1 | |
| SCHEMBL299448 | 0.91 | PIK3CA (0.52) | PIK3CABRD4NEK1NTRK1KIT | |
| SCHEMBL297762 | 0.89 | PIK3CA (0.54) | PIK3CANTRK1KITMAPK10CYP3A4 | |
| SCHEMBL298351 | 0.86 | PIK3CA (0.49) | PIK3CATNIKBRD4NEK1CYP3A4 | |
| SCHEMBL298357 | 0.86 | CYP3A4 (0.52) | PIK3CABRD4CYP3A4 | |
| SCHEMBL3698939 | 0.86 | PIK3CA (0.49) | PIK3CABRD4NEK1NTRK1KIT | |
| SCHEMBL298808 | 0.84 | CYP3A4 (0.49) | PIK3CABRD4CYP3A4MAP2K7MAP2K4 | |
| SCHEMBL299508 | 0.84 | CYP3A4 (0.53) | PIK3CABRD4CYP3A4MAP2K7MAP2K4 | |
| SCHEMBL297350 | 0.84 | CYP3A4 (0.51) | PIK3CATNIKBRD4KITCYP3A4 | |
| SCHEMBL878738 | 0.84 | TNIK (0.55) | PIK3CATNIKAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | PIK3CA 277/4885TNIK 1393/4885BRD4 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.